Self‐Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD‐L1 Upregulation
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202502120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Xiayun Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Breast Neoplasms, Histone Deacetylases, Adjuvants, Immunologic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Areas of Colleges and Universities in Guangdong Province.
Abstract (Originalsprache)
The low immunogenicity and immunosuppressive phenotype of breast cancer significantly limit the effectiveness of immunotherapy. This study reveals that histone deacetylases (HDACs) are upregulated in breast cancer, while lower levels of HDACs and higher levels of programmed cell death ligand 1 (PD‐L1) are associated with better patient prognosis. Moreover, Trichostatin A (TSA) is confirmed to suppress HDACs and increase PD‐L1 expression. Building on these insights, a self‐promoting targeted immunostimulant (SPT‐IS) is developed to activate breast cancer immunity by epigenetically upregulating PD‐L1. SPT‐IS can selectively accumulate in PD‐L1‐overexpressing breast cancer cells for co‐delivery of Chlorin e6 (Ce6) and TSA. Notably, SPT‐IS‐induced epigenetic upregulation of PD‐L1 creates a self‐promoting tumor‐targeting loop that enhances drug delivery efficiency. Besides, SPT‐IS generates reactive oxygen species (ROS) to kill tumor cells and release damage‐associated molecular patterns, increasing tumor immunogenicity. Additionally, the epigenetic regulation ability of SPT‐IS upregulates immunomodulatory cytokines and stimulates T cell cytotoxicity for immune activation. Immunological results confirm robust immunomodulatory effects of SPT‐IS, significantly enhancing tumor‐infiltrating lymphocytes recruitment and proliferation, leading to notable anti‐tumor efficacy. These findings highlight the potential of a self‐promoting targeted strategy to enhance drug delivery and provide an epigenetic approach to boost the immune response against breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences, Guangzhou…
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074.
- Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575.
- Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575.
- Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, 117544.
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599.
ORCID-Profile: Xiaoyuan Chen
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Areas of Colleges and Universities in Guangdong Province
- Guangdong Basic and Applied Basic Research Foundation
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Chen, X., Lu, L., Liang, Z., Yu, B., Shao, Z., Li, J., Cen, Y., Liu, Y., Li, S., & Chen, X. (2025). Self‐Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD‐L1 Upregulation. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202502120
Vancouver
Chen X, Lu L, Liang Z, Yu B, Shao Z, Li J, et al. Self‐Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD‐L1 Upregulation. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202502120
BibTeX
@article{Chen2025,
author = {Chen, Xiayun and Lu, Lichong and Liang, Ziqi and Yu, Baixue and Shao, Zhouchuan and Li, Jianqiao and Cen, Yi and Liu, Yibin and Li, Shiying and Chen, Xiaoyuan},
title = {Self‐Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD‐L1 Upregulation},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202502120}
}
EUVIMED